Rufinamide ‘Approvable’ for Some Seizures

The Food and Drug Administration has issued an “approvable” letter for the use of rufinamide as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome and as adjunctive treatment for partial-onset seizures with and without secondary generalization, according to the manufacturer of the antiepileptic drug.